Processa Pharma Analyst Ratings
Processa Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 04/04/2023 | 814.29% | Benchmark | $9 → $4 | Maintains | Speculative Buy |
| 04/03/2023 | 585.71% | Oppenheimer | $5 → $3 | Maintains | Outperform |
| 01/12/2023 | 1042.86% | Maxim Group | $9 → $5 | Maintains | Buy |
| 04/19/2022 | 1957.14% | Maxim Group | → $9 | Initiates Coverage On | → Buy |
| 08/03/2021 | 4471.43% | Oppenheimer | → $20 | Initiates Coverage On | → Outperform |
| 08/02/2021 | 4471.43% | Oppenheimer | → $20 | Initiates Coverage On | → Outperform |
| 10/28/2020 | 2642.86% | Craig-Hallum | → $12 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/17/2023 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 04/04/2023 | 814.29% | 基準 | 9 美元 → 4 美元 | 維護 | 投機性買入 |
| 04/03/2023 | 585.71% | 奧本海默 | 5 美元 → 3 美元 | 維護 | 跑贏大盤 |
| 01/12/2023 | 1042.86% | Maxim 集團 | 9 美元 → 5 美元 | 維護 | 買 |
| 04/19/2022 | 1957.14% | Maxim 集團 | → 9 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/03/2021 | 4471.43% | 奧本海默 | → 20 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 08/02/2021 | 4471.43% | 奧本海默 | → 20 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 10/28/2020 | 2642.86% | Craig-Hallum | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Processa Pharma (PCSA)?
Processa Pharma（PCSA）的目標價格是多少？
The latest price target for Processa Pharma (NASDAQ: PCSA) was reported by Maxim Group on November 17, 2023. The analyst firm set a price target for $0.00 expecting PCSA to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
Maxim集團於2023年11月17日公佈了Processa Pharma（納斯達克股票代碼：PCSA）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計PCSA將在12個月內降至12個月內（可能下跌-100.00％）。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Processa Pharma (PCSA)?
Processa Pharma（PCSA）的最新分析師評級是多少？
The latest analyst rating for Processa Pharma (NASDAQ: PCSA) was provided by Maxim Group, and Processa Pharma downgraded their hold rating.
Processa Pharma（納斯達克股票代碼：PCSA）的最新分析師評級由Maxim集團提供，Processa Pharma下調了持有評級。
When is the next analyst rating going to be posted or updated for Processa Pharma (PCSA)?
Processa Pharma（PCSA）的下一次分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Processa Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Processa Pharma was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Processa Pharma的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Processa Pharma的最新評級是在2023年11月17日公佈的，因此您應該預計下一個評級將在2024年11月17日左右公佈。
Is the Analyst Rating Processa Pharma (PCSA) correct?
分析師評級流程 Process Pharma（PCSA）是否正確？
While ratings are subjective and will change, the latest Processa Pharma (PCSA) rating was a downgraded with a price target of $0.00 to $0.00. The current price Processa Pharma (PCSA) is trading at is $0.44, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Process Pharma（PCSA）評級已下調，目標股價爲0.00美元至0.00美元。Processa Pharma（PCSA）目前的交易價格爲0.44美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。